GenYi Qu1, Zhengsheng Liu2, Guang Yang1, Yong Xu1, Maolin Xiang1, Cheng Tang1. 1. Department of Urology, Zhuzhou Central Hospital, Zhuzhou 412007, China. 2. Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Abstract
BACKGROUND: Bladder cancer (BLCA) is one of the most common urinary tract malignant tumors. It is associated with poor outcomes, and its etiology and pathogenesis are not fully understood. There is great hope for immunotherapy in treating many malignant tumors; therefore, it is worthwhile to explore the use of immunotherapy for BLCA. METHODS: Gene expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA), and immune-related genes (IRGs) were downloaded from the Immunology Database and Analysis Portal. Differentially-expressed and survival-associated IRGs in patients with BLCA were identified using computational algorithms and Cox regression analysis. We also performed functional enrichment analysis. Based on IRGs, we employed multivariate Cox analysis to develop a new prognostic index. RESULTS: We identified 261 IRGs that were differentially expressed between BLCA tissue and adjacent tissue, 30 of which were significantly associated with the overall survival (all P<0.01). According to multivariate Cox analysis, nine survival-related IRGs (MMP9, PDGFRA, AHNAK, OAS1, OLR1, RAC3, IGF1, PGF, and SH3BP2) were high-risk genes. We developed a prognostic index based on these IRGs and found it accurately predicted BLCA outcomes associated with the TNM stage. Intriguingly, the IRG-based prognostic index reflected infiltration of macrophages. CONCLUSIONS: An independent IRG-based prognostic index provides a practical approach for assessing patients' immune status and prognosis with BLCA. This index independently predicted outcomes of BLCA.
BACKGROUND:Bladder cancer (BLCA) is one of the most common urinary tract malignant tumors. It is associated with poor outcomes, and its etiology and pathogenesis are not fully understood. There is great hope for immunotherapy in treating many malignant tumors; therefore, it is worthwhile to explore the use of immunotherapy for BLCA. METHODS: Gene expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA), and immune-related genes (IRGs) were downloaded from the Immunology Database and Analysis Portal. Differentially-expressed and survival-associated IRGs in patients with BLCA were identified using computational algorithms and Cox regression analysis. We also performed functional enrichment analysis. Based on IRGs, we employed multivariate Cox analysis to develop a new prognostic index. RESULTS: We identified 261 IRGs that were differentially expressed between BLCA tissue and adjacent tissue, 30 of which were significantly associated with the overall survival (all P<0.01). According to multivariate Cox analysis, nine survival-related IRGs (MMP9, PDGFRA, AHNAK, OAS1, OLR1, RAC3, IGF1, PGF, and SH3BP2) were high-risk genes. We developed a prognostic index based on these IRGs and found it accurately predicted BLCA outcomes associated with the TNM stage. Intriguingly, the IRG-based prognostic index reflected infiltration of macrophages. CONCLUSIONS: An independent IRG-based prognostic index provides a practical approach for assessing patients' immune status and prognosis with BLCA. This index independently predicted outcomes of BLCA.
Entities:
Keywords:
The Cancer Genome Atlas; bladder cancer; immune-related genes; immunogenomic landscape; prognostic index
Authors: Rafael Stroggilos; Maria Frantzi; Jerome Zoidakis; Marika Mokou; Napoleon Moulavasilis; Emmanouil Mavrogeorgis; Anna Melidi; Manousos Makridakis; Konstantinos Stravodimos; Maria G Roubelakis; Harald Mischak; Antonia Vlahou Journal: Cancers (Basel) Date: 2022-05-21 Impact factor: 6.575
Authors: Ji Chen; Boyu Lv; Yating Zhan; Kai Zhu; Rongrong Zhang; Bo Chen; Yan Jin; Yeping Li; Jianjian Zheng; Changyong Lin Journal: Front Oncol Date: 2022-02-14 Impact factor: 6.244